Lau C, Oh H, Aw T
Vaccines (Basel). 2025; 13(1).
PMID: 39852788
PMC: 11768752.
DOI: 10.3390/vaccines13010009.
Grove J, Mayne E, Burgers W, Blackburn J, Jugwanth S, Stevens W
S Afr J Infect Dis. 2024; 36(1):286.
PMID: 39376942
PMC: 11457558.
DOI: 10.4102/sajid.v36i1.286.
Favresse J, Tre-Hardy M, Gillot C, Cupaiolo R, Wilmet A, Beukinga I
Heliyon. 2024; 10(16):e36116.
PMID: 39247272
PMC: 11379571.
DOI: 10.1016/j.heliyon.2024.e36116.
Gillot C, Bayart J, Maloteau V, Dogne J, Douxfils J, Favresse J
Case Rep Infect Dis. 2024; 2024:9163490.
PMID: 39246664
PMC: 11380708.
DOI: 10.1155/2024/9163490.
Lippi G, Henry B, Pighi L, De Nitto S, Salvagno G
Adv Lab Med. 2023; 4(2):175-184.
PMID: 38075941
PMC: 10701493.
DOI: 10.1515/almed-2023-0008.
Validation of a rapid SARS-CoV-2 antibody test in general practice.
Domen J, Verbakel J, Adriaenssens N, Scholtes B, Peeters B, Bruyndonckx R
BMJ Open. 2023; 13(5):e069997.
PMID: 37130685
PMC: 10163333.
DOI: 10.1136/bmjopen-2022-069997.
Resistance towards ChadOx1 nCoV-19 in an 83 Years Old Woman Experiencing Vaccine Induced Thrombosis with Thrombocytopenia Syndrome.
Gillot C, Favresse J, Maloteau V, Mathieux V, Dogne J, Mullier F
Vaccines (Basel). 2022; 10(12).
PMID: 36560466
PMC: 9781243.
DOI: 10.3390/vaccines10122056.
Antibody tests for identification of current and past infection with SARS-CoV-2.
Fox T, Geppert J, Dinnes J, Scandrett K, Bigio J, Sulis G
Cochrane Database Syst Rev. 2022; 11():CD013652.
PMID: 36394900
PMC: 9671206.
DOI: 10.1002/14651858.CD013652.pub2.
Comparison of two antibody screening systems for SARS-CoV-2 antibody detection in recovered and vaccinated subjects - test performance and possible indicators for immunity.
Jonczyk R, Stanislawski N, Seiler L, Ahani S, Bueltemeier A, Stahl F
J Clin Virol. 2022; 157:105322.
PMID: 36279696
PMC: 9576262.
DOI: 10.1016/j.jcv.2022.105322.
Serum SARS-CoV-2 Antigens for the Determination of COVID-19 Severity.
Favresse J, Bayart J, David C, Gillot C, Wieers G, Roussel G
Viruses. 2022; 14(8).
PMID: 36016276
PMC: 9415151.
DOI: 10.3390/v14081653.
Evaluation of antibody titer kinetics and SARS-CoV-2 infections in a large cohort of healthcare professionals ten months after administration of the BNT162b2 vaccine.
Ferrari D, Ambrosi A, Di Resta C, Tomaiuolo R, Locatelli M, Banfi G
J Immunol Methods. 2022; 506:113293.
PMID: 35660546
PMC: 9161676.
DOI: 10.1016/j.jim.2022.113293.
SARS-CoV-2 seroprevalence among Vancouver public school staff in British Columbia, Canada: a cross-sectional study.
Goldfarb D, Masse L, Watts A, Hutchison S, Muttucomaroe L, Bosman E
BMJ Open. 2022; 12(4):e057846.
PMID: 35383082
PMC: 8983418.
DOI: 10.1136/bmjopen-2021-057846.
Comparative study of six SARS-CoV-2 serology assays: Diagnostic performance and antibody dynamics in a cohort of hospitalized patients for moderate to critical COVID-19.
Chamkhi S, Dhaouadi T, Sfar I, Mokni S, Jebri A, Mansouri D
Int J Immunopathol Pharmacol. 2022; 36:20587384211073232.
PMID: 35113728
PMC: 8819577.
DOI: 10.1177/20587384211073232.
Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol.
Adriaenssens N, Scholtes B, Bruyndonckx R, Verbakel J, De Sutter A, Heytens S
BMJ Open. 2022; 12(1):e054688.
PMID: 35105642
PMC: 8804304.
DOI: 10.1136/bmjopen-2021-054688.
Development of a quantitative COVID-19 multiplex assay and its use for serological surveillance in a low SARS-CoV-2 incidence community.
Guarino C, Larson E, Babasyan S, Rollins A, Joshi L, Laverack M
PLoS One. 2022; 17(1):e0262868.
PMID: 35061843
PMC: 8782306.
DOI: 10.1371/journal.pone.0262868.
Low incidence of COVID-19 in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a tertiary medical center during the 2020 pandemic.
Frundt T, Kuballa L, Lutgehetman M, Norz D, Arend H, Brehm T
PLoS One. 2021; 16(12):e0258450.
PMID: 34941875
PMC: 8699616.
DOI: 10.1371/journal.pone.0258450.
Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine.
Ferrari D, Clementi N, Criscuolo E, Ambrosi A, Corea F, Di Resta C
Vaccines (Basel). 2021; 9(11).
PMID: 34835288
PMC: 8620373.
DOI: 10.3390/vaccines9111357.
Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers.
Bayart J, Douxfils J, Gillot C, David C, Mullier F, Elsen M
Vaccines (Basel). 2021; 9(10).
PMID: 34696200
PMC: 8540417.
DOI: 10.3390/vaccines9101092.
Reply to Schulte-Pelkum, J. Comment on "Favresse et al. Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. 2021, , 556".
Favresse J, Gillot C, Douxfils J
Microorganisms. 2021; 9(9).
PMID: 34576743
PMC: 8468564.
DOI: 10.3390/microorganisms9091849.
Efficient Maternal to Neonate Transfer of Neutralizing Antibodies after SARS-CoV-2 Vaccination with BNT162b2: A Case-Report and Discussion of the Literature.
Douxfils J, Gillot C, De Gottal E, Vandervinne S, Bayart J, Dogne J
Vaccines (Basel). 2021; 9(8).
PMID: 34452032
PMC: 8402444.
DOI: 10.3390/vaccines9080907.
